The Challenge of Evaluating AI Products in Healthcare

https://www.techpolicy.press/the-challenge-of-evaluating-ai-products-in-healthcare/

Publish Date: 2026-02-23 07:10:00

Source Domain: www.techpolicy.press

Emerging Challenges in AI Evaluation: As AI-enabled products in healthcare rise, there is a growing need for established benchmarks to ensure their safety and efficacy, leading to a notable evaluation crisis.
Regulatory and Stakeholder Involvement: Multiple regulatory bodies, including federal health regulators, state medical boards, and various state legislatures, are working on frameworks to evaluate AI products, revealing regulatory gaps and overlaps.
Clinical Validation Concerns: Many recalled AI-enabled medical devices lack clinical validation, raising concerns about their safety and efficacy as highlighted by research and FDA activities.
Risk in Mental Health Applications: With the rise of generative AI in mental health, there are heightened concerns about potential risks, leading to increased scrutiny, particularly regarding AI chatbots designed for wellness rather than direct therapy.
Regulatory Shifts: There has been a shift in regulatory focus toward evaluating mental health risks, with state laws like California’s restricting certain AI applications, and federal entities investigating market practices.
Efforts to Improve Evaluation Methods: The National Institute of Standards and Technology (NIST) is leading efforts to develop comprehensive evaluation frameworks for AI, aiming to address construct validity and generalizability challenges.
Increasing Collaboration: Various collaborative efforts, such as the AI Evaluator Forum and the Health AI Partnership, are focused on developing high-standard evaluation methods and frameworks to ensure the reliability and efficacy of AI tools.
Continuous Monitoring and Post-Deployment Evaluation: It’s essential for AI tools to not just be evaluated before deployment but also continually monitored post-deployment to ensure sustained safety and effectiveness.